Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.
Latest
Popular

Updates from the BCON trial: Longterm outcomes of hypoxia modification in bladder preservation

Dr Yee Pei Song - The Christie NHS Foundation Trust, Manchester, UK
Updates from the BCON trial: Longterm outcomes of hypoxia modification in bladder preservation ( Dr Yee Pei Song - The Christie NHS Foundation Trust, Manchester, UK )
18 Feb 2019

KEYNOTE-365 Cohort A: Pembrolizumab plus olaparib in docetaxel-pretreated patients with mCRPC

Prof Evan Yu - Fred Hutchinson Cancer Research Center, Seattle, USA
KEYNOTE-365 Cohort A: Pembrolizumab plus olaparib in docetaxel-pretreated patients with mCRPC ( Prof Evan Yu - Fred Hutchinson Cancer Research Center, Seattle, USA )
18 Feb 2019

STREAM trial: Enzalutamide and androgen deprivation therapy with salvage radiation in men with high-risk PSA recurrent PC

Prof Andrew Armstrong - Duke Cancer Institute, Durham, USA
STREAM trial: Enzalutamide and androgen deprivation therapy with salvage radiation in men with high-risk PSA recurrent PC ( Prof Andrew Armstrong - Duke Cancer Institute, Durham, USA )
15 Feb 2019

KEYNOTE-426: Pembrolizumab and axitinib vs sunitinib in advanced renal cell carcinoma

Prof Brian Rini - Cleveland Clinic, Cleveland, USA
KEYNOTE-426: Pembrolizumab and axitinib vs sunitinib in advanced renal cell carcinoma ( Prof Brian Rini - Cleveland Clinic, Cleveland, USA )
14 Feb 2019

ASCO GU 2019 renal highlights

Dr Toni Choueiri - Dana-Farber Cancer Institute, Boston, USA
ASCO GU 2019 renal highlights ( Dr Toni Choueiri - Dana-Farber Cancer Institute, Boston, USA )
14 Feb 2019

ARCHES trial: Androgen deprivation therapy with enzalutamide or placebo in mHSPC

Prof Andrew Armstrong - Duke Cancer Institute, Durham, USA
ARCHES trial: Androgen deprivation therapy with enzalutamide or placebo in mHSPC ( Prof Andrew Armstrong - Duke Cancer Institute, Durham, USA )
14 Feb 2019

Latest from Tivo-3: Tivozanib for refractory advanced renal cell carcinoma

Prof Brian Rini - Cleveland Clinic, Cleveland, USA
Latest from Tivo-3: Tivozanib for refractory advanced renal cell carcinoma ( Prof Brian Rini - Cleveland Clinic, Cleveland, USA )
14 Feb 2019

Sacituzumab govitecan in patients with previously treated metastatic urothelial cancer

Dr Scott Tagawa - Weill Cornell Medicine, New York City, USA
Sacituzumab govitecan in patients with previously treated metastatic urothelial cancer ( Dr Scott Tagawa - Weill Cornell Medicine, New York City, USA )
14 Feb 2019

Updates from KEYNOTE 57: Pembrolizumab for patients with bladder cancer

Dr Arjun Balar - NYU Langone Health, New York City, USA
Updates from KEYNOTE 57: Pembrolizumab for patients with bladder cancer ( Dr Arjun Balar - NYU Langone Health, New York City, USA )
14 Feb 2019

CHEIRON study: Docetaxel plus enzalutamide versus docetaxel as first-line chemotherapy for patients with mCRPC

Dr Orazio Caffo - Santa Chiara Hospital, Trento, Italy
CHEIRON study: Docetaxel plus enzalutamide versus docetaxel as first-line chemotherapy for patients with mCRPC ( Dr Orazio Caffo - Santa Chiara Hospital, Trento, Italy )
14 Feb 2019

Changes to the CME system in France

Anne Depaigne-Loth - French National Agency for Continuing Professional Development, Paris, France
Changes to the CME system in France ( Anne Depaigne-Loth - French National Agency for Continuing Professional Development, Paris, France )
29 Jan 2019

The importance of CME publishing

Lawrence Sherman - Academy for Global Interprofessional Learning and Education (AGILE), Thonex, Switzerland
The importance of CME publishing ( Lawrence Sherman - Academy for Global Interprofessional Learning and Education (AGILE), Thonex, Switzerland )
29 Jan 2019

More from ecancer

Register with ecancer to receive our newsletter

Register here

Explore patient resources at ecancerpatient

Visit site

Find out more about ecancer and the work we do

About ecancer

Support ecancer's work by making a donation